[Skip to Navigation]
September 8, 2015

Treatment Decision Making and Genetic Testing for Breast Cancer: Mainstreaming Mutations

Author Affiliations
  • 1Departments of Medicine and Health Management and Policy, University of Michigan, Ann Arbor
  • 2Departments of Medicine and Health Research and Policy, Stanford University, Stanford, California
  • 3Breast Service, Memorial Sloan-Kettering Cancer Center, New York, New York
  • 4Department of Surgery, Weill Medical College of Cornell University, New York, New York
JAMA. 2015;314(10):997-998. doi:10.1001/jama.2015.8088

Rates of genetic testing for women with diagnosed breast cancer appear to be increasing substantially. More than one-fourth of patients diagnosed today undergo testing,1 multiple-gene sequencing panels are replacing testing limited to BRCA1/2 mutations, and genetic counselors report ordering more tests.2 Within the next few years it is likely that most patients with newly diagnosed breast cancer will undergo genetic testing to inform their risk of developing a subsequent cancer. There is already a widening gap between the availability of more expansive genetic testing and the relative importance of results to treatment decisions.